Nasus Pharma Announces Health Canada Has Issued A No-Objection Letter Allowing The Company To Proceed With A Phase 2 Clinical Trial Of NS002, Its Intranasal Epinephrine Powder Being Developed For The Treatment Of Anaphylaxis

Nasus Pharma Ltd. (NYSE:NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced that it recently received a No-Objection Letter from Health Canada, the country's primary regulatory authority for drugs and medical products, for the Company's planned Phase 2 clinical study of NS002, its investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis.

The Health Canada authorization marks an important regulatory milestone in the NS002 development program. This clearance confirms the acceptability of the proposed trial design, supporting safety data, and manufacturing information, and enables Nasus to advance towards its planned Phase 2 clinical study.

"We believe receiving this approval from Health Canada represents an important milestone in our mission to transform anaphylaxis treatment," said Dan Teleman, Chief Executive Officer of Nasus Pharma. "For millions suffering from severe allergies, the fear of needles and inconvenience of carrying autoinjectors leads to poor compliance and potentially life-threatening outcomes. Our Phase 2 study aims to further evaluate how NS002, powered by our proprietary Nasax® technology, can deliver epinephrine effectively while offering patients the ease and convenience of a simple nasal spray. We look forward to initiating the study as soon possible."